ReviewThe AAPS journal2007
Vectors for airway gene delivery.
Review in The AAPS journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Advances in gene transfer technologies: comparing viral and non-viral vectors for therapeutic applications.3 Biotech · 2026Review
- Progress in Respiratory Gene Therapy.Human gene therapy · 2022Review
- Gene Therapy for Acute Respiratory Distress Syndrome.Frontiers in physiology · 2021Review
- Structural Polymorphism of Single pDNA Condensates Elicited by Cationic Block Polyelectrolytes.Polymers · 2020Review
- Recent advances in the development of gene delivery systems.Biomaterials research · 2019Review
- A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium.Biomaterials · 2013Review
- Viral and nonviral delivery systems for gene delivery.Advanced biomedical research · 2012Article
- Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells.Biomaterials · 2011Article
- N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Gene therapy for ALI/ARDS.Critical care clinics · 2011Review
- AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects.Investigative ophthalmology & visual science · 2011Review
- Nucleolin-mediated cellular trafficking of DNA nanoparticle is lipid raft and microtubule dependent and can be modulated by glucocorticoid.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2010Article
- A poly(ethylene) glycolylated peptide for ocular delivery compacts DNA into nanoparticles for gene delivery to post-mitotic tissues in vivo.The journal of gene medicine · 2010Article
- Optimization of Streptomyces bacteriophage phi C31 integrase system to prevent post integrative gene silencing in pulmonary type II cells.Experimental & molecular medicine · 2009Article
- Nonviral gene delivery: principle, limitations, and recent progress.The AAPS journal · 2009Review
- A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles.PloS one · 2009Article
- The silent (R)evolution of polymeric nucleic acid therapeutics.Pharmaceutical research · 2008Article
- Nanoparticle applications in ocular gene therapy.Vision research · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delivery of genes to the airway epithelium for therapeutic purposes seemed easy at first, because the epithelial cells interface with the environment and are therefore accessible. However, problems encountered were more substantial than were originally expected. Nonviral systems may be preferred for long-term gene expression, for they can be dosed repeatedly. Two nonviral gene transfer systems have been in clinical trials, lipid-mediated gene transfer and DNA nanoparticles. Both have sufficient efficiency to be candidates for correction of the cystic fibrosis defect, and both can be dosed repeatedly. However, lipid-mediated gene transfer in the first generation provokes significant inflammatory toxicity, which may be engineered out by adjustments of the lipids, the plasmid CpG content, or both. Both lipid-mediated gene transfer and DNA nanoparticles in the first generation have short duration of expression, but reengineering of the plasmid DNA to contain mostly eukaryotic sequences may address this problem. Considerable advances in the understanding of the cellular uptake and expression of these agents and in their practical utility have occurred in the last few years; these advances are reviewed here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.